A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. [electronic resource]
Producer: 20170327Description: 1349-56 p. digitalISSN:- 1545-5017
- Adolescent
- Antimetabolites, Antineoplastic -- therapeutic use
- Antineoplastic Agents, Alkylating -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Buthionine Sulfoximine -- adverse effects
- Child
- Child, Preschool
- Drug Synergism
- Female
- Glutamate-Cysteine Ligase -- antagonists & inhibitors
- Glutathione -- therapeutic use
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cells -- metabolism
- Humans
- Male
- Melphalan -- adverse effects
- Myeloablative Agonists -- therapeutic use
- Neoplasm Recurrence, Local -- drug therapy
- Neuroblastoma -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.